JP2019512495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512495A5 JP2019512495A5 JP2018548236A JP2018548236A JP2019512495A5 JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5 JP 2018548236 A JP2018548236 A JP 2018548236A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2019512495 A5 JP2019512495 A5 JP 2019512495A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- salt
- methylpiperazin
- pyran
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 9
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 8
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 8
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- -1 tetrahydro-2H-pyran-4-ylamino Chemical group 0.000 claims 2
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US62/314700 | 2016-03-29 | ||
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| US62/368343 | 2016-07-29 | ||
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512495A JP2019512495A (ja) | 2019-05-16 |
| JP2019512495A5 true JP2019512495A5 (OSRAM) | 2020-04-09 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548236A Pending JP2019512495A (ja) | 2016-03-29 | 2017-03-27 | 急性骨髄性白血病の治療のための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190117649A1 (OSRAM) |
| EP (1) | EP3436014A4 (OSRAM) |
| JP (1) | JP2019512495A (OSRAM) |
| KR (1) | KR20180124055A (OSRAM) |
| CN (1) | CN108883109A (OSRAM) |
| BR (1) | BR112018069111A2 (OSRAM) |
| CA (1) | CA3018155A1 (OSRAM) |
| MX (1) | MX2018011975A (OSRAM) |
| RU (1) | RU2018134167A (OSRAM) |
| WO (1) | WO2017170348A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| US12433867B2 (en) | 2019-02-22 | 2025-10-07 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| KR20200102949A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| CA3131461C (en) * | 2019-04-03 | 2024-06-25 | Akihiko Sasaki | Pharmaceutical composition comprising gilteritinib and method of producing the same |
| CA3145391A1 (en) | 2019-06-27 | 2020-12-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| BR112022007210A2 (pt) * | 2019-10-14 | 2022-07-05 | Astrazeneca Ab | Terapia de combinação para tratar malignidade hematológica |
| CA3155215A1 (en) * | 2019-10-21 | 2021-04-29 | Srikant Viswanadha | Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia |
| KR20240128987A (ko) | 2021-12-30 | 2024-08-27 | 바이오메아 퓨전, 인크. | Flt3의 억제제로서의 피라진 화합물 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512495A5 (OSRAM) | ||
| RU2018134167A (ru) | Комбинированная терапия для лечения острого миелоидного лейкоза | |
| JP5417385B2 (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
| TWI791467B (zh) | 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）、奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）、５-氟尿嘧啶及甲醯四氫葉酸（ｌｅｕｃｏｖｏｒｉｎ）之組合療法治療胃癌 | |
| JP2016040316A5 (OSRAM) | ||
| JP2009542699A5 (OSRAM) | ||
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| JP2015524444A5 (OSRAM) | ||
| JP2016516816A5 (OSRAM) | ||
| JP2020530467A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) | ||
| JP2016529285A5 (OSRAM) | ||
| JP2020523359A5 (OSRAM) | ||
| JP2016521755A5 (OSRAM) | ||
| JP2016515586A5 (OSRAM) | ||
| CN103370066B (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JP2017526695A5 (OSRAM) | ||
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| JP2009536956A5 (OSRAM) | ||
| JP2020536121A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| JP2011500589A5 (OSRAM) | ||
| JP2016510040A5 (OSRAM) | ||
| JP2023030112A (ja) | 肥満細胞疾患の処置のための方法及び医薬組成物 |